Randomized Controlled Trial of the Smart O2O Model Development for Chronic Diseases Management Through Digital Health
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Nov 28, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new approach to managing chronic diseases like diabetes and hypertension through digital health. The goal is to see how well the O2O (Online to Offline) service model can help patients in Pyeongchang-gun, South Korea, by providing personalized healthcare plans and support using an online platform. Participants will be randomly assigned to either a treatment group, where they will receive tailored care, or a control group. The study will include 1,000 adults, primarily those aged 18 to 70, who have either diabetes (including pre-diabetes) or hypertension. Older adults over 70 can also join, provided they are comfortable using a specific mobile app designed for this trial.
If you decide to participate, you can expect an initial health exam, followed by a customized care plan. The Smart Healthcare Center will monitor your health and send you helpful health messages. High-risk patients might receive a glucose monitor to help track their levels. The trial aims to improve your health and manage chronic conditions more effectively through this innovative digital approach. It's important to note that participants will need a compatible mobile device and must be willing to accept random group assignments for the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Participation aged 18 to 70 years
- • 2. Participation diagnosed with diabetes (including borderline diabetes) or hypertension (including borderline hypertension)
- However, we will exercise flexibility in age eligibility, allowing patients above 70 years to participate if they meet the following criteria:
- • Digital Literacy: Participants above 70 years must demonstrate proficiency in digital technology and the ability to effectively use the mobile application "Value Health," which has been specially developed for this research.
- Exclusion Criteria:
- • 1. Incompatible Mobile Device: Individuals using older mobile phones that are not compatible with the "Value of Health" application will be excluded.
- • 2. Participation in Concurrent Research: Individuals who are currently participating in another research program involving smart health technology will not be eligible for inclusion in our study.
- • 3. Non-Acceptance of Random Assignment or Participation: Individuals who do not agree to be randomly assigned to either the treatment or control group or who do not wish to engage in our research program will be excluded from participation.
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Juwhan Oh, MD, PhD
Principal Investigator
Seoul National University Hospital & College of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported